BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析

◆英語タイトル:BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH27812FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥50,625見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

BioMarin Pharmaceutical Inc (BMRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company. It develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facilities in Novato, California. It conducts its business operations in the US, Europe, Latin America, the Middle East and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Feb 18,2021: BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
Nov 05,2020: BioMarin announces third quarter 2020 total revenues of $477 million
Oct 05,2020: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joins BioMarin as Head of Research and Early Development
Sep 25,2020: Pomerantz law firm announces the filing of a class action against BioMarin Pharmaceuticals and certain officers – BMRN
Aug 04,2020: BioMarin announces second quarter 2020 total revenue growth of 11% to $430 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
BioMarin Pharmaceutical Inc – Key Facts
BioMarin Pharmaceutical Inc – Key Employees
BioMarin Pharmaceutical Inc – Key Employee Biographies
BioMarin Pharmaceutical Inc – Major Products and Services
BioMarin Pharmaceutical Inc – History
BioMarin Pharmaceutical Inc – Company Statement
BioMarin Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
BioMarin Pharmaceutical Inc – Business Description
Product Category: Aldurazyme
Overview
Performance
Product Category: Brineura
Overview
Performance
Product Category: Firdapse
Overview
Performance
Product Category: Kuvan
Overview
Performance
Product Category: Naglazyme
Overview
Performance
Product Category: Palynziq
Overview
Performance
Product Category: Vimizim
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
BioMarin Pharmaceutical Inc – Corporate Strategy
BioMarin Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
BioMarin Pharmaceutical Inc – Strengths
BioMarin Pharmaceutical Inc – Weaknesses
BioMarin Pharmaceutical Inc – Opportunities
BioMarin Pharmaceutical Inc – Threats
BioMarin Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 18, 2021: BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
Nov 05, 2020: BioMarin announces third quarter 2020 total revenues of $477 million
Oct 05, 2020: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joins BioMarin as Head of Research and Early Development
Sep 25, 2020: Pomerantz law firm announces the filing of a class action against BioMarin Pharmaceuticals and certain officers – BMRN
Aug 04, 2020: BioMarin announces second quarter 2020 total revenue growth of 11% to $430 million
Jul 02, 2020: BioMarin Pharmaceutical: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jun 29, 2020: BioMarin Promotes Company Veteran, Brian R. Mueller, to executive vice president, CFO
May 11, 2020: BioMarin announces proposed private offering of $500 Million of senior subordinated convertible notes
May 03, 2020: BioMarin extends Gene Therapy leadership with DiNAQOR in a preclinical collaboration and license agreement to develop Gene Therapies for Rare Genetic Cardiomyopathies
Apr 29, 2020: BioMarin announces first quarter 2020 total revenue growth of 25% to $502 million
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont...1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wesfarmers Ltd (WES)-石油・ガス分野:企業M&A・提携分析
    Summary Wesfarmers Limited (Wesfarmers) is a diversified company that has business operations in retail and industrial activities. Its retail activities include supermarkets, liquor, hotels and convenience stores; department stores; home improvement and office supplies; and apparel retailing. The co …
  • Air Products and Chemicals, Inc.:企業の戦略・SWOT・財務情報
    Air Products and Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Air Products and Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • K-Electric Ltd (KEL):企業の財務・戦略的SWOT分析
    K-Electric Ltd (KEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Rolta India Ltd (ROLTA):企業の財務・戦略的SWOT分析
    Rolta India Ltd (ROLTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Cholamandalam Investment and Finance Company Ltd (CHOLAFIN):企業の財務・戦略的SWOT分析
    Cholamandalam Investment and Finance Company Ltd (CHOLAFIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Vanguard Natural Resources, LLC (VNRSQ)-石油・ガス分野:企業M&A・提携分析
    Summary Vanguard Natural Resources, LLC (Vanguard) is an upstream company. It acquires, produces, and develops oil and natural gas properties. The company owns Green River Basin, Permian Basin, Piceance Basin, Gulf Coast Basin, Arkoma Basin, Big Horn Basin, Williston Basin, Anadarko Basin, and Wind …
  • Surgutneftegas (SNGS):企業の財務・戦略的SWOT分析
    Surgutneftegas (SNGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ASKA Pharmaceutical Co Ltd (4514):製薬・医療:M&Aディール及び事業提携情報
    Summary ASKA Pharmaceutical Co Ltd (ASKA) is a pharmaceutical company that offers quasi-drugs, foods, medical devices and veterinary medicines. The company imports and export pharmaceuticals and medical devices. Its activities comprise production, drug information, and research and development servi …
  • TRACON Pharmaceuticals Inc (TCON):企業の財務・戦略的SWOT分析
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its le …
  • Duravit AG:企業の戦略・SWOT・財務情報
    Duravit AG - Strategy, SWOT and Corporate Finance Report Summary Duravit AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Weyerhaeuser Co (WY):企業の財務・戦略的SWOT分析
    Weyerhaeuser Co (WY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Unilever Pakistan Limited:企業の戦略・SWOT・財務情報
    Unilever Pakistan Limited - Strategy, SWOT and Corporate Finance Report Summary Unilever Pakistan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Unum Group:戦略・SWOT・企業財務分析
    Unum Group - Strategy, SWOT and Corporate Finance Report Summary Unum Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Raschig GmbH:企業の戦略的SWOT分析
    Raschig GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Molnlycke Health Care AB:医療機器:M&Aディール及び事業提携情報
    Summary Molnlycke Health Care AB (Molnlycke), a subsidiary of Investor AB, is a medical device company. The company manufactures and markets single-use surgical and wound care products. It offers a range of surgical and wound care products; infection prevention solutions; prevention and treatment so …
  • Macquarie Bank Ltd:企業のM&A・事業提携・投資動向
    Macquarie Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Macquarie Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Enable Midstream Partners LP (ENBL):石油・ガス:M&Aディール及び事業提携情報
    Summary Enable Midstream Partners, LP (Enable), a subsidiary of CenterPoint Energy Inc, owns, operates, and develops natural gas and crude oil infrastructure assets. It is a limited partnership among CenterPoint Energy, OGE Energy and ArcLight Capital Partners, LLC. The company offers crude oil and …
  • Toro Energy Limited (TOE):企業の財務・戦略的SWOT分析
    Toro Energy Limited (TOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Silgan Holdings Inc.:企業の戦略・SWOT・財務分析
    Silgan Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Silgan Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • SpineGuard SA (ALSGD):医療機器:M&Aディール及び事業提携情報
    Summary SpineGuard SA (SpineGuard) is a medical device company that designs, develops and markets spine surgery products. The company offers PediGuard, a device that detects possible vertebral cortex perforation during pedicle preparation. It provides offers screw placement and alerts to surgeon pri …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆